Summit Therapeutics (SMMT) is a publicly traded Healthcare sector company. As of July 16, 2026, SMMT trades at $14.36 with a market cap of $12.01B and a P/E ratio of -10.44. SMMT moved -3.72% today. Year to date, SMMT is -13.84%; over the trailing twelve months it is -38.14%. Its 52-week range spans $12.55 to $36.91. Analyst consensus is buy with an average price target of $29.25. Rallies surfaces SMMT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for SMMT shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $14.36 |
| Market Cap | $12.01B |
| P/E Ratio | -10.44 |
| EPS | $-1.44 |
| Dividend Yield | 0.00% |
| 52-Week High | $36.91 |
| 52-Week Low | $12.55 |
| Volume | 776.43K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-1.08B |
| Gross Margin | 0.00% |
13 analysts cover SMMT: 0 strong buy, 8 buy, 4 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $29.25.